Business Context and Reporting Period
Company: United Therapeutics Corporation (UTHR)
Filing Type: Form 8-K (Current Report)
Date of Report: March 9, 2026
Event: Approval and execution of a new share repurchase program and associated accelerated share repurchase (ASR) agreements.
Key Financial Metrics and Transaction Details
This filing details a capital allocation event rather than periodic financial performance. Key metrics include:
- Total Repurchase Authorization: $2.0 billion of common stock authorized by the Board on March 8, 2026, valid until March 9, 2027.
- Initial ASR Commitment: $1.5 billion aggregate upfront payment to Citibank, N.A. (Citi) scheduled for March 11, 2026.
- ASR Structure:
- Uncollared ASR: $750 million; initial delivery of ~992,120 shares (approx. 70% of total expected shares).
- Collared ASR: $750 million; initial delivery of ~708,657 shares (approx. 50% of total expected shares).
- Settlement Dates: Uncollared ASR terminates in Q2 2026; Collared ASR terminates in Q3 2026.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the initiation of a significant capital return program. The company has committed $1.5 billion of cash immediately to repurchase shares, representing 75% of the newly authorized $2.0 billion program. This action reduces the company's cash balance upon settlement and decreases the number of outstanding shares.
Outlook, Risks, and Management Commentary
Management Commentary: The Board approved the program to return capital to shareholders. The company utilized a mix of uncollared and collared ASR structures to manage share price volatility and execution timing.
Risks and Contingencies:
- Settlement Variability: The final number of shares repurchased depends on the average daily volume-weighted average price (VWAP) during the term of the agreements.
- Collar Provisions: The Collared ASR includes minimum and maximum share amount limits. At final settlement, the company may receive additional shares or, in limited circumstances, be required to make a cash payment or deliver shares to Citi.
- Liquidity Impact: The immediate outflow of $1.5 billion will impact short-term liquidity, though the filing does not quantify remaining cash reserves.
Investor Verification Checklist
- Verify the company's current cash and cash equivalents balance to assess the impact of the $1.5 billion upfront payment.
- Review the specific terms of the "collar" in the Collared ASR to understand the downside risk of potential cash payments at settlement.
- Monitor the stock price performance between March 11, 2026, and the Q2/Q3 2026 settlement dates to estimate final share counts.
- Confirm the remaining $500 million of the authorized program is available for future open-market repurchases.